Atlas Trials

Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients

Clinical trial NCT03028103 · COMPLETED

Trial details

NCT number
NCT03028103
Sponsor
Epizyme, Inc.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Diffuse Large B Cell LymphomaPrimary Mediastinal LymphomaMantle Cell LymphomaAdvanced Solid TumorMarginal Zone Lymphoma
Start date
2017-03-27
Primary completion
2019-10-31
Enrollment
32

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.